SolutionsAbout UsOur WorkContact
All Work

News

Sort by
All Work
White Papers
Blog Post
Data Snacks
Videos
News
Sort By
All Work
White Papers
Blog Post
Data Snacks
Videos
News
News
March 5, 2026
Instant, AI-Driven Diabetes Market Research

Our AI instantly delivers powerful, actionable diabetes insights from one of the world’s richest diabetes datasets.

Read More
News
March 5, 2026
Instant, AI-Driven Diabetes Market Research

Our AI instantly delivers powerful, actionable diabetes insights from one of the world’s richest diabetes datasets.

Read More
News
January 1, 2023
Research by Trevor Bell Published in Current Diabetes Reports

dQ&A’s Trevor Bell publishes research in Current Diabetes Reports, offering insights into the critical role psychosocial issues play in diabetes management.

Read More
News
January 1, 2023
Research by Trevor Bell Published in Current Diabetes Reports

dQ&A’s Trevor Bell publishes research in Current Diabetes Reports, offering insights into the critical role psychosocial issues play in diabetes management.

Read More
News
September 1, 2022
Diabetes Digital Health: Drastic Differences in Perceived Benefits

Our semi-annual study of digital health apps in diabetes, known as “DHx” (Digital Health Experience), finds broad variation in patient satisfaction.

Read More
News
September 1, 2022
Diabetes Digital Health: Drastic Differences in Perceived Benefits

Our semi-annual study of digital health apps in diabetes, known as “DHx” (Digital Health Experience), finds broad variation in patient satisfaction.

Read More
News
September 1, 2022
EASD 2022 Abstract: Anxiety & Glycemic Control in EU Diabetes

We're proud to share Evelyn Cox’s EASD 2022 abstract revealing mental-health disparities among Europeans with diabetes by nationality, gender, and age.

Read More
News
September 1, 2022
EASD 2022 Abstract: Anxiety & Glycemic Control in EU Diabetes

We're proud to share Evelyn Cox’s EASD 2022 abstract revealing mental-health disparities among Europeans with diabetes by nationality, gender, and age.

Read More
News
May 1, 2022
Type 2 Insulin Insights Data Service

Our T2 Insulin Insights is a semi-annual Research Service that explores the lived experience of people with type 2 diabetes who take insulin.

Read More
News
May 1, 2022
Type 2 Insulin Insights Data Service

Our T2 Insulin Insights is a semi-annual Research Service that explores the lived experience of people with type 2 diabetes who take insulin.

Read More
News
April 1, 2022
Major Grocery Chains Failing People with Diabetes

A national dQ&A survey of over 5,000 people with diabetes found wide variation in grocery store quality, with Aldi, Publix, Costco, H-E-B, and Hy-Vee rated highest.

Read More
News
April 1, 2022
Major Grocery Chains Failing People with Diabetes

A national dQ&A survey of over 5,000 people with diabetes found wide variation in grocery store quality, with Aldi, Publix, Costco, H-E-B, and Hy-Vee rated highest.

Read More
News
March 1, 2022
Announcing Our First Look Insights Qualitative Research Service

We are excited to announce dQ&A’s new syndicated qualitative research service, First Look Insights.

Read More
News
March 1, 2022
Announcing Our First Look Insights Qualitative Research Service

We are excited to announce dQ&A’s new syndicated qualitative research service, First Look Insights.

Read More
News
January 1, 2022
COVID-19 Booster Rates in U.S. Diabetes Community

This survey shows COVID-19 booster rates are higher in U.S. adults with diabetes than the general population, but vary by race, income, and location.

Read More
News
January 1, 2022
COVID-19 Booster Rates in U.S. Diabetes Community

This survey shows COVID-19 booster rates are higher in U.S. adults with diabetes than the general population, but vary by race, income, and location.

Read More
News
June 1, 2021
Panel Member Survey on Provention Bio’s Teplizumab

We surveyed panel members about the FDA advisory on Provention Bio’s teplizumab to delay type 1 diabetes—discover their top concerns and expected impact.

Read More
News
June 1, 2021
Panel Member Survey on Provention Bio’s Teplizumab

We surveyed panel members about the FDA advisory on Provention Bio’s teplizumab to delay type 1 diabetes—discover their top concerns and expected impact.

Read More
2 / 5
Subscribe to our newsletter
Receive our latest updates and
insights in your inbox.
ContactAbout
Our WorkSolutions
PrivacyTerms & Conditions
© 2025 dQ&A all rights reserved